Headquartered in Seattle, WA Fiscal year ends December NASDAQ: ADPT adaptivebiotech.com
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company operates through two business segments: Minimal Residual Disease (MRD), which represents 92% of revenue and centers on its FDA-cleared clonoSEQ assay for detecting and monitoring residual cancer cells in patients with blood cancers; and Immune Medicine, which applies the company's proprietary immune medicine platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics for diseases including cancer and autoimmune disorders. The company's platform translates the massive genetics of the adaptive immune system with scale, precision, and speed. Adaptive has announced plans to separate its MRD and Immune Medicine businesses into distinct entities. The company trades on the Nasdaq under the ticker ADPT. Updated
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Friday afternoon's analyst upgrades and downgrades included Chubb, Domino’s, Lam Research, Moderna, Riot Blockchain and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Microsoft, Oracle, Tesla, Virgin Galactic and more.
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the biology of the adaptive immune system to transform the diagnosis and treatment of disease.
The Wall Street consensus 12-month price target for ADPT is $28.31.
